Continued support is requested to further develop flow cytometry (FCM) as a diagnostic and prognostic tool for the management of patients with malignant lymphomas employing genotypic, phenotypic, cytokinetic and therapy-related parameters. These studies will focus on the two major subgroups of diffuse large cell (DLCL) and follicular small cleaved lymphoma (FSCL) to systematically examine the heterogeneity in lineage, differentiation, proliferation, pertinent oncogene products including receptors, and therapy- related cellular features (e.g. expression of glucocorticoid and interferon receptors, multidrug resistance phenotype and adriamycin cellular uptake). Multiparameter FCM technology will be employed to study the interaction between these cellular features and their expression in relationship to tumor cells defined either on the basis of DNA aneuploidy or monoclonal light chain reactivity. Advances are anticipated in the understanding of the fundamentally different clinical behavior of follicular small cleaved vs diffuse large cell lymphomas and the biologically intriguing issue of transformation from low to higher histologic grade. A second segment of this proposal is directed to develop new cytometric probes to study the molecular mechanisms of neoplasia including oncogene products related to growth and differentiation and expression of cellular receptors. As result of this research, we anticipate major progress towards biologically and molecularly based objective and quantitative diagnosis of lymphomas, where morphologic interpretation has been fraught with problems of reproducibility and clinical relevance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA028771-10
Application #
3168332
Study Section
(SSS)
Project Start
1980-07-01
Project End
1993-08-31
Budget Start
1989-09-22
Budget End
1990-08-31
Support Year
10
Fiscal Year
1989
Total Cost
Indirect Cost
Name
University of Arkansas for Medical Sciences
Department
Type
Schools of Medicine
DUNS #
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Grigoriev, V G; Grigorieva, I; Moerman, E J et al. (1996) Senescent fibroblasts as feeder cells for lymphoid cell cloning. Anal Biochem 236:250-4
Hardin, J; MacLeod, S; Grigorieva, I et al. (1994) Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 84:3063-70
Ridley, R C; Xiao, H; Hata, H et al. (1993) Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood 81:767-74
Hata, H; Xiao, H; Petrucci, M T et al. (1993) Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. Blood 81:3357-64
Kreitman, R J; Siegall, C B; FitzGerald, D J et al. (1992) Interleukin-6 fused to a mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma. Blood 79:1775-80
Thomas, X; Xiao, H Q; Chang, R et al. (1992) Circulating B lymphocytes in multiple myeloma patients contain an autocrine IL-6 driven pre-myeloma cell population. Curr Top Microbiol Immunol 182:201-7
Barlogie, B; Gale, R P (1992) Multiple myeloma and chronic lymphocytic leukemia: parallels and contrasts. Am J Med 93:443-50
Alexanian, R; Barlogie, B; Gutterman, J (1991) Alpha-interferon combination therapy of resistant myeloma. Am J Clin Oncol 14:188-92
el-Naggar, A K; Batsakis, J G; Teague, K et al. (1991) Single- and double-stranded RNA measurements by flow cytometry in solid neoplasms. Cytometry 12:330-5
Dimopoulos, M A; Barlogie, B; Smith, T L et al. (1991) High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med 115:931-5

Showing the most recent 10 out of 51 publications